{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:15:36Z","timestamp":1789942536533,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1007\/s11864-004-0007-5","type":"journal-article","created":{"date-parts":[[2007,6,28]],"date-time":"2007-06-28T08:41:03Z","timestamp":1183020063000},"page":"63-73","source":"Crossref","is-referenced-by-count":12,"title":["Positron emission tomography scanning for the diagnosis and management of lung cancer"],"prefix":"10.1007","volume":"5","author":[{"given":"Bruce R.","family":"Line","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"7_CR1","first-page":"210","volume":"16","author":"ME Phelps","year":"1975","unstructured":"Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM: Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 1975, 16:210\u2013224.","journal-title":"J Nucl Med"},{"key":"7_CR2","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMoa022136","volume":"348","author":"D Lardinois","year":"2003","unstructured":"Lardinois D, Weder W, Hany TF, et al.: Staging of non-small cell lung cancer with integrated positron emission tomography and computed tomography. N Engl J Med 2003, 348:2500\u20132507.","journal-title":"N Engl J Med"},{"key":"7_CR3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1148\/radiology.207.2.9577492","volume":"207","author":"PD Shreve","year":"1998","unstructured":"Shreve PD, Steventon RS, Deters EC, et al.: Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology 1998, 207:431\u2013437.","journal-title":"Radiology"},{"key":"7_CR4","first-page":"2110","volume":"36","author":"D Delbeke","year":"1995","unstructured":"Delbeke D, Videlefsky S, Patton JA, et al.: Rest myocardial perfusion\/metabolism imaging using simultaneous dual-isotope acquisition SPECT with technetium-99m-MIBI\/fluorine-18-FDG. J Nucl Med 1995, 36:2110\u20132119.","journal-title":"J Nucl Med"},{"key":"7_CR5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0272-5231(21)01152-7","volume":"14","author":"GA Lillington","year":"1993","unstructured":"Lillington GA, Caskey CI: Evaluation and management of solitary and multiple pulmonary nodules. Clin Chest Med 1993, 14:111\u2013119.","journal-title":"Clin Chest Med"},{"key":"7_CR6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jama.1958.02990030008003","volume":"166","author":"CA Good","year":"1958","unstructured":"Good CA, Wilson TW: The solitary circumscribed pulmonary nodule: study of seven hundred five cases encountered roentgenologically in a period of three and one-half years. J Am Med Assoc 1958, 166:210\u2013215.","journal-title":"J Am Med Assoc"},{"key":"7_CR7","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1378\/chest.112.2.416","volume":"112","author":"NA Dewan","year":"1997","unstructured":"Dewan NA, Shehan CJ, Reeb SD, et al.: Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. Chest 1997, 112:416\u2013422. Using Bayesian analysis, FDG-PET was found to be a better predictor of malignancy in solitary pulmonary nodules compared to the standard criteria based on the patient\u2019s age, history of previous malignancy, smoking history, size and edge of nodule, and presence or absence of nodule calcification.","journal-title":"Chest"},{"key":"7_CR8","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jama.285.7.914","volume":"285","author":"MK Gould","year":"2001","unstructured":"Gould MK, Maclean CC, Kuschner WG, et al.: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001, 285:914\u2013924.","journal-title":"JAMA"},{"key":"7_CR9","first-page":"1771","volume":"35","author":"VJ Lowe","year":"1994","unstructured":"Lowe VJ, Hoffman JM, Delong DM, et al.: Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994, 35:1771\u20131776.","journal-title":"J Nucl Med"},{"key":"7_CR10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1378\/chest.104.4.997","volume":"104","author":"NA Dewan","year":"1993","unstructured":"Dewan NA, Gupta NC, Redepenning LS, et al.: Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest 1993, 104:997\u20131002.","journal-title":"Chest"},{"key":"7_CR11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1148\/radiology.184.2.1620844","volume":"184","author":"NC Gupta","year":"1992","unstructured":"Gupta NC, Frank AR, Dewan NA, et al.: Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992, 184:441\u2013444.","journal-title":"Radiology"},{"key":"7_CR12","first-page":"1016","volume":"39","author":"K Higashi","year":"1998","unstructured":"Higashi K, Ueda Y, Seki H, et al.: Fluorine-18-FDG-PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998, 39:1016\u20131020.","journal-title":"J Nucl Med"},{"key":"7_CR13","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2214\/ajr.170.5.9574618","volume":"170","author":"JJ Erasmus","year":"1998","unstructured":"Erasmus JJ, McAdams HP, Patz EF Jr, et al.: Evaluation of primary pulmonary carcinoid tumors using FDG-PET. AJR Am J Roentgenol 1998, 170:1369\u20131373.","journal-title":"AJR Am J Roentgenol"},{"key":"7_CR14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1148\/radiology.188.2.8327702","volume":"188","author":"EF Patz","year":"1993","unstructured":"Patz EF Jr, Lowe VJ, Hoffman JM, et al.: Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993, 188:487\u2013490.","journal-title":"Radiology"},{"key":"7_CR15","first-page":"355","volume":"34","author":"KJ Langen","year":"1993","unstructured":"Langen KJ, Braun U, Rota KE, et al.: The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993, 34:355\u2013359.","journal-title":"J Nucl Med"},{"key":"7_CR16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1378\/chest.88.2.206","volume":"88","author":"RJ McKenna","year":"1985","unstructured":"McKenna RJ Jr, Libshitz HI, Mountain CE, McMurtrey MJ: Roentgenographic evaluation of mediastinal nodes for preoperative assessment in lung cancer. Chest 1985, 88:206\u2013210.","journal-title":"Chest"},{"key":"7_CR17","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1136\/thx.50.12.1267","volume":"50","author":"T Arita","year":"1995","unstructured":"Arita T, Kuramitsu T, Kawamura M, et al.: Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax 1995, 50:1267\u20131269.","journal-title":"Thorax"},{"key":"7_CR18","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1378\/chest.110.4.1004","volume":"110","author":"T Arita","year":"2004","unstructured":"Arita T, Matsumoto T, Kuramitsu T, et al.: Is it possible to differentiate malignant mediastinal nodes from benign nodes by size? Reevaluation by CT, transesophageal echocardiography, and nodal specimen. Chest 1996, 110:1004\u20131008.","journal-title":"Chest"},{"key":"7_CR19","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1148\/radiology.213.2.r99nv46530","volume":"213","author":"BA Dwamena","year":"1999","unstructured":"Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL: Metastases from non-small cell lung cancer: mediastinal staging in the 1990s: meta-analytic comparison of PET and CT. Radiology 1999, 213:530\u2013536.","journal-title":"Radiology"},{"key":"7_CR20","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1148\/radiology.215.3.r00jn29886","volume":"215","author":"MA Farrell","year":"2000","unstructured":"Farrell MA, McAdams HP, Herndon JE, Patz EF Jr: Non-small cell lung cancer: FDG-PET for nodal staging in patients with stage I disease. Radiology 2000, 215:886\u2013890. A retrospective study to determine the accuracy of FDG-PET in the evaluation of regional lymph nodes in patients with stage I NSCLC. The overall sensitivity, specificity, and positive and negative predictive values for PET of regional lymph nodal metastases were 82%, 86%, 47%, and 97%, respectively. FDGPET enables accurate staging of regional lymph node disease in patients with stage I NSCLC. The authors think that a negative PET scan in these patients suggests that mediastinoscopy is unnecessary and these patients can proceed directly to thoracotomy.","journal-title":"Radiology"},{"key":"7_CR21","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1183\/09031936.97.10112529","volume":"10","author":"T Bury","year":"1997","unstructured":"Bury T, Dowlati A, Paulus P, et al.: Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997, 10:2529\u20132534.","journal-title":"Eur Respir J"},{"key":"7_CR22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1200\/JCO.2001.19.1.111","volume":"19","author":"V Kalff","year":"2001","unstructured":"Kalff V, Hicks RJ, MacManus MP, et al.: Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small cell lung cancer: a prospective study. J Clin Oncol 2001, 19:111\u2013118.","journal-title":"J Clin Oncol"},{"key":"7_CR23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0360-3016(01)01824-7","volume":"52","author":"K Mah","year":"2002","unstructured":"Mah K, Caldwell CB, Ung YC, et al.: The impact of (18)FDG-PET on target and critical organs in CTbased treatment planning of patients with poorly defined non-small cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002, 52:339\u2013350.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7_CR24","first-page":"752","volume":"43","author":"MA Seltzer","year":"2002","unstructured":"Seltzer MA, Yap CS, Silverman DH, et al.: The impact of PET on the management of lung cancer: the referring physician\u2019s perspective. J Nucl Med 2002, 43:752\u2013756.","journal-title":"J Nucl Med"},{"key":"7_CR25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1200\/JCO.2001.19.1.111","volume":"19","author":"V Kalff","year":"2001","unstructured":"Kalff V, Hicks RJ, MacManus MP, et al.: Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small cell lung cancer: a prospective study. J Clin Oncol 2001, 19:111\u2013118.","journal-title":"J Clin Oncol"},{"key":"7_CR26","first-page":"814","volume":"40","author":"RE Coleman","year":"1999","unstructured":"Coleman RE: PET in lung cancer. J Nucl Med 1999, 40:814\u2013820. Whole-body PET studies detect metastatic disease that is unsuspected by conventional imaging and demonstrate some of the anatomic abnormalities detected by CT to be benign lesions. Management changes have been reported in up to 41% of patients on the basis of the results of whole-body studies.","journal-title":"J Nucl Med"},{"key":"7_CR27","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1007\/s00259-002-0775-8","volume":"29","author":"SM Eschmann","year":"2002","unstructured":"Eschmann SM, Friedel G, Paulsen F, et al.: FDG-PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging 2002, 29:804\u2013808. A prospective study staging 101 patients with NSCLC before combined neoadjuvant therapy (ie, preoperative radio-chemotherapy). The results of PET were compared with results obtained by mediastinoscopy, CT, bone scan, and abdominal ultrasonography. PET proved to be highly accurate for the detection of lymph node metastases (sensitivity 96%, specificity 73%, positive predictive value 88%, negative predictive value 89%, and accuracy 88%) and distant metastases (25 of 101 patients, all previously unknown). PET findings changed further treatment in 29% of patients. FDG-PET was the most accurate noninvasive diagnostic procedure for the staging of advanced NSCLC. FDG-PET was highly recommended to select patients for neoadjuvant or other stage-dependent treatment modalities.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7_CR28","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1378\/chest.117.2.346","volume":"117","author":"S Kosuda","year":"2000","unstructured":"Kosuda S, Ichihara K, Watanabe M, et al.: Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan. Chest 2000, 117:346\u2013353. A decision-tree sensitivity analysis based on the two competing strategies of chest CT alone versus chest CT plus chest FDG-PET. The chest CT plus chest FDG-PET strategy yielded an expected life expectancy gain of 0.607 years (7.3 months) per patient compared to the alternative strategy of chest CT alone.","journal-title":"Chest"},{"key":"7_CR29","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1007\/s00259-003-1199-9","volume":"30","author":"P Verboom","year":"2003","unstructured":"Verboom P, Van Tinteren H, Hoekstra OS, et al.: Costeffectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging 2003, 30:1444\u20131449. The cost effectiveness of fluorine FDG-PET added to the conventional diagnostic work-up was studied before invasive staging and thoracotomy in 188 patients with (suspected) NSCLC. Despite the additional PET costs, the total costs were lower in the PET group, mainly because of a reduction in the number of futile operations. The additional use of PET in the staging of patients with NSCLC is feasible, safe, and cost saving from a clinical and economic perspective.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7_CR30","unstructured":"Antoch G, Stattaus J, Nemat AT, et al.: Non-small cell lung cancer: dual-modality PET\/CT in preoperative staging.\n                           Radiology 2003, in press. Use of dual-modality PET-CT significantly increases the number of patients with correctly staged NSCLC. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of regional lymph node staging were 89%, 94%, 89%, 94%, and 93% with PET-CT, respectively, 89%, 89%, 80%, 94%, and 89% with PET, respectively, and 70%, 59%, 50%, 77%, and 63% with CT, respectively."},{"key":"7_CR31","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/S0003-4975(98)01055-8","volume":"66","author":"WJ Scott","year":"1998","unstructured":"Scott WJ, Shepherd J, Gambhir SS: Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg 1998, 66:1876\u20131883.","journal-title":"Ann Thorac Surg"},{"key":"7_CR32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S0003-4975(03)00888-9","volume":"76","author":"RJ Cerfolio","year":"2003","unstructured":"Cerfolio RJ, Ojha B, Bryant AS, et al.: The role of FDGPET scan in staging patients with non-small cell carcinoma. Ann Thorac Surg 2003, 76:861\u2013866. A prospective study of 400 patients with NSCLC with CT and FDG-PET within 1 month before surgery. All suspicious N2 lymph nodes by chest CT or FDG-PET scan were biopsied. Patients who were N2 and M1 negative underwent pulmonary resection and complete thoracic lymphadenectomy. The FDGPET had a higher sensitivity (71% vs 43%; P < 0.001), positive predictive value (44% vs 31%; P < 0.001), negative predictive value (91% vs 84%; P = 0.006), and accuracy (76% vs 68%; P = 0.037) compared to CT scan for N2 lymph nodes. FDG-PET had a higher sensitivity (67% vs 41%; P < 0.001) but lower specificity (78% vs 88%; P = 0.009) compared to CT scan for N1 lymph nodes. FDG-PET led to unnecessary mediastinoscopy in 38 patients. FDG-PET accurately upstaged 28 patients (7%) with unsuspected metastasis and downstaged 23 patients (6%). FDG-PET more accurately staged the mediastinum. The authors suggest that a positive FDG-PET scan indicates the need for a tissue biopsy at that location.","journal-title":"Ann Thorac Surg"},{"key":"7_CR33","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1148\/radiology.215.3.r00jn29886","volume":"215","author":"MA Farrell","year":"2000","unstructured":"Farrell MA, McAdams HP, Herndon JE, Patz EF Jr: Non-small cell lung cancer: FDG-PET for nodal staging in patients with stage I disease. Radiology 2000, 215:886\u2013890.","journal-title":"Radiology"},{"key":"7_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0169-5002(02)00446-4","volume":"39","author":"CJ Hoekstra","year":"2003","unstructured":"Hoekstra CJ, Stroobants SG, Hoekstra OS, et al.: The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer 2003, 39:151\u2013157. A prospective study with FDG-PET involving 57 patients with stage IIIA-N2 NSCLC to assess its value in the selection of this patient group. The results show that a substantial group of patients was understaged using the conventional staging algorithm. FDG-PET improves the selection of patients suitable for combined modality therapy.","journal-title":"Lung Cancer"},{"key":"7_CR35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1148\/radiology.202.2.9015071","volume":"202","author":"HC Steinert","year":"1997","unstructured":"Steinert HC, Hauser M, Allemann F, et al.: Non-small cell lung cancer: nodal staging with FDG-PET versus CT with correlative lymph node mapping and sampling. Radiology 1997, 202:441\u2013446. Prospective comparison of the accuracy of FDG-PET with CT in the nodal staging of NSCLC in 47 patients. The sensitivity of PET and CT for the staging of N2 or N3 disease in mediastinal nodes was 89% and 57%, respectively, specificity was 99% and 94%, respectively, positive predictive value was 96% and 76%, respectively, negative predictive value was 97% and 87%, respectively, and accuracy was 96% and 85%, respectively. In assigning the correct N stage, PET was correct in 96% and CT in 79% of cases. PET with FDG may be superior to CT for nodal staging of NSCLC.","journal-title":"Radiology"},{"key":"7_CR36","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1200\/JCO.1998.16.6.2142","volume":"16","author":"JF Vansteenkiste","year":"1998","unstructured":"Vansteenkiste JF, Stroobants SG, De Leyn PR, et al.: Lymph node staging in non-small cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998, 16:2142\u20132149. A study to compare the accuracy of CT and FDG-PET in locoregional lymph node staging of NSCLC. In the detection of locally advanced disease (N2\/N3), the sensitivity, specificity, and accuracy of CT were 75%, 63%, and 68%, respectively. For PET plus CT, it was 93%, 95%, and 94%, respectively (P = 0.0004). PET plus CT is significantly more accurate compared to CT alone in lymph node staging of NSCLC. The very high negative predictive value of mediastinal PET could reduce the need for mediastinal invasive staging studies in NSCLC substantially.","journal-title":"J Clin Oncol"},{"key":"7_CR37","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1378\/chest.120.2.521","volume":"120","author":"NC Gupta","year":"2001","unstructured":"Gupta NC, Tamim WJ, Graeber GG, et al.: Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest 2001, 120:521\u2013527.","journal-title":"Chest"},{"key":"7_CR38","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1067\/mtc.2002.123130","volume":"124","author":"H Vesselle","year":"2002","unstructured":"Vesselle H, Pugsley JM, Vallieres E, Wood DE: The impact of fluorodeoxyglucose F 18 positron emission tomography on the surgical staging of non-small cell lung cancer. J Thorac Cardiovasc Surg 2002, 124:511\u2013519. A prospective study to evaluate the accuracy and anatomic information provided by FDG-PET in 142 patients with potentially resectable NSCLC. PET revealed unsuspected distant metastases in 24 of 142 patients (16.9%) and unsuspected pleural implants in six other patients. Nodal stage was surgically established in 118 cases. In 35 of 142 patients (24.6%), PET directed the evaluation away from routine bronchoscopy and mediastinoscopy staging that would have resulted in inappropriate treatment selection. PET correctly differentiated resectable stages IA through IIIA (N1) from stages IIIA (N2) through IV in 88.7% of cases. In identifying N2 or N3 disease, PET had an accuracy of 90.7%, a sensitivity of 80.9%, a specificity of 96%, and positive and negative predictive values of 91.9% and 90.1%, respectively.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"7_CR39","first-page":"267","volume":"49","author":"TC Hsia","year":"2002","unstructured":"Hsia TC, Shen YY, Yen RF, et al.: Comparing whole-body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer. Neoplasma 2002, 49:267\u2013271. Forty-eight patients with biopsy-proven NSCLC and suspected to have stage IV disease underwent whole-body bone scan and FDG-PET to detect bone metastases. The data suggest that FDG-PET has the same sensitivity and a better accuracy compared to Tc-99m methylene diophosphate bone scan to detect metastatic bone lesions in patients with biopsy-proven NSCLC and suspected to have stage IV disease.","journal-title":"Neoplasma"},{"key":"7_CR40","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1200\/JCO.2003.12.004","volume":"21","author":"WA Weber","year":"2003","unstructured":"Weber WA, Petersen V, Schmidt B, et al.: Positron emission tomography in non-small cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003, 21:2651\u20132657. A prospective evaluation of the use of FDG-PET to predict response to chemotherapy in 57 patients with advanced NSCLC. In NSCLC, reduction of metabolic activity after one cycle of chemotherapy is closely correlated with final outcome of therapy. Using metabolic response as an endpoint may shorten the duration of phase II studies evaluating new cytotoxic drugs and may decrease the morbidity and costs of therapy in nonresponding patients.","journal-title":"J Clin Oncol"},{"key":"7_CR41","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.2003.07.054","volume":"21","author":"Manus MP Mac","year":"2003","unstructured":"Mac Manus MP, Hicks RJ, Matthews JP, et al.: Positron emission tomography is superior to computed tomography scanning for response assessment after radical radiotherapy or chemoradiotherapy in patients with non-small cell lung cancer. J Clin Oncol 2003, 21:1285\u20131292. Seventy-three patients with NSCLC underwent PET and CT scans before and after radical radiotherapy or chemoradiotherapy. Follow-up PET scans were performed at a median time of 70 days after radiotherapy. PET response was significantly associated with survival duration (P < 0.0001). In NSCLC, a single early post-treatment PET scan is a better predictor of survival than CT response, stage, or pretreatment performance status.","journal-title":"J Clin Oncol"},{"key":"7_CR42","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/S0360-3016(02)03038-9","volume":"54","author":"NC Choi","year":"2002","unstructured":"Choi NC, Fischman AJ, Niemierko A, et al.: Doseresponse relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG-PET after preoperative chemoradiotherapy in locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2002, 54:1024\u20131035. In this study, the authors determined the dose-response relationship between the probability of tumor control on the basis of pathologic tumor response and the residual metabolic rate of glucose in response to preoperative chemoradiotherapy in locally advanced NSCLC. The correlation between the gradient of residual activity after chemoradiotherapy and pathologic response is an inverse dose-response relationship.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-004-0007-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-004-0007-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-004-0007-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-004-0007-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T13:11:45Z","timestamp":1652620305000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-004-0007-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["7"],"URL":"https:\/\/doi.org\/10.1007\/s11864-004-0007-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}